Poliovirus type 2 antigen (formaldehyde inactivated)

DB10796ApprovedInvestigationalVaccinesInactivated Poliovirus Vaccine

Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for... The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells.

First approval
Canada, 2000 · United States, 1990 · European Union, 2021
Also known as
Inactivated poliomyelitis vaccine (D.C.O.) type 2 MEF1 · Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1 · Inactivated poliovirus type II · Poliovirus vaccine inactivated, type 2 (MEF-1)
Brand names
  • Hexacima
  • Infanrix Hexa
  • Ipol
  • Kinrix
  • Pediarix
  • Pentacel
  • Quadracel
  • Vaxelis

Resolves to

Compound
UNII23JE9KDF4R
Clinical / RWD
RxNorm763098

What you can answer from here — as of April 02, 2025

132Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
182Marketed productsAcross 10 countries and 17 labellers
Sign in

Which other approved drugs treat the same conditions as Poliovirus type 2 antigen (formaldehyde inactivated), and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In